Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the “Company”), comments on the new COVID Vaccine policy adopted by the US FDA.

Satsuma, a unit of a Japanese drugmaker with U.S. headquarters in Durham, said its treatment, called Atzumi, received its new ...

For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...

Pfizer also plans to make a $100 million equity investment in the Chinese biotechnolgoy company after the transaction closes, ...

The High Court here has allowed an application by former Bersatu Youth chief Adam Asmuni to submit new evidence in his appeal ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

If the initiative proceeds as planned, it will mark a pivotal shift in the regulatory landscape, introducing both efficiencies and novel ...

The White House has launched a new program focused on leveraging technology and private sector partnerships to find new ways to quickly produce key pharmaceutical ingredients and finished drugs at the ...

The initiatives reflect the latest measures from federal agencies to reduce and ultimately replace animal testing in drug development and ...

Apellis Pharmaceuticals focuses on creating medicines targeting eye diseases and rare neurological diseases. Read why I rate ...

The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who ...

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine ...